Insulin Resistance and Metabolic Health

Marc: Resistance of disease.

Marc: I don't think it's a disease. I think it's us. I think it's a program that's part of our body's response to overfeeding and inadequate exercise. It's a response to the nutritional milieu that we create in the modern world.

Brent: Welcome to The Life Lab by Death Clock. I'm your host, Brent Franson. The mission of Death Clock is to help 100 million people live ten years longer. Today, we speak with Dr. Marc Hellerstein about insulin resistance and metabolic health. Dr. Hellerstein is professor of human nutrition at the University of California, Berkeley. He occupies two endowed chairs at Berkeley: the Doris Calloway Chair and the Dr. Robert C. and Veronica Atkins Chair.

Brent: He's also Professor of Endocrinology, Metabolism, and Nutrition in the Department of Medicine at the University of California, San Francisco. He's a wonderful guest who spent his entire career studying insulin resistance and the impact that it has on our health. Insulin resistance and metabolic health are going to have a huge impact on how long we live. So in this conversation, we go deep into what insulin resistance is, how we think about it, and how we can be healthier.

Brent: Hope you enjoy.

Brent: Dr. Marc Hellerstein, welcome to the show.

Marc: Thanks for having me.

Brent: So today we're going to talk about insulin resistance, metabolic health, and diabetes. All of these topics are wrapped together and matter for health and longevity. But before we do that, can you just give us a sense of your day job, your background, and a short bio?

Marc: Yeah, sure. So I'm a physician. I got a medical degree at Yale many years ago and a PhD at MIT in nutritional biochemistry. I did a medical and endocrine residency, and I've been at this dream job at UC Berkeley in the Department of Metabolic Biology and Nutrition, and at UCSF in the medicine and endocrinology departments. I've spent my whole life researching metabolic diseases.

Brent: When we talk about metabolic health and insulin resistance, I think we've all heard those terms. But even after having conversations on the show about metabolic health, if somebody asked, "What is metabolic health?", I think I would have a hard time defining it. So, what is metabolic health?

Brent: When we think about insulin resistance, how should we think about it?

Marc: Good questions. Let's start with insulin resistance because that one's easy. Insulin resistance is when insulin is not doing in the body what it's supposed to do, which means we have to know what it's supposed to do. And we do know. Insulin is the great anabolic hormone in our bodies. It tells the body you're fed and that nutrients are present.

Marc: So insulin makes carbohydrates stored as glycogen, makes fat stored as triglycerides, makes amino acids stored as proteins, and makes cells grow. It's the hormone of growth and storage. Resistance means it's not doing what it's supposed to do. And the beta cells in the pancreas that make insulin are so smart and sensitive that they will change and make more insulin in response to tiny changes.

Marc: Early on, insulin is not working great, so the beta cells in the pancreas make more insulin, leading to high insulin or hyperinsulinemia. Metabolic health is a bigger question. We'll get to that later when we talk about metabolic syndrome, which is highly correlated with insulin resistance.

Brent: Our body produces insulin, and as a hormone, it helps in the process of storing fats, proteins, and nutrients. When we are resistant to insulin, it's not doing that job as well. Why does that matter?

Marc: The reason we care is that it's highly associated with the major diseases of the modern world. Cardiovascular disease is the number one killer in the world now. For the first time in human history, instead of infantile diarrhea, it's Western diseases. About 70 years ago, it was discovered that insulin can be high—especially in early diabetes, not low like in what was called juvenile diabetes.

Marc: This is paradoxical: how can insulin be high while your blood sugar is also high? Then it was found that insulin is high in many other conditions: high blood pressure, bad lipids, cardiovascular disease, and cancer. Insulin resistance is a major risk factor for pretty much all Western conditions.

Marc: Most of the Western cancers that kill us are associated with insulin resistance. So we care about it because it's associated with disease.

Brent: How do we measure this? To understand my risk for heart disease, I would get a blood test or a lipid panel to check my ApoB and LDL levels.

Brent: I know you have some perspectives on the utility of LDL, but it's pretty straightforward to understand risk for heart disease. On the risk side for type 2 diabetes and metabolic health, we can look at blood glucose from a metabolic panel, hemoglobin A1C, or fasting insulin.

Brent: Are those the right biomarkers? Which ones do you care about more or less for understanding if someone has insulin resistance and assessing their overall metabolic health?

Marc: Doctors rarely measure insulin resistance directly because it's hard to do. You can measure insulin, but there's a problem. Let's focus first on adult type 2 diabetes, which accounts for 90% of diabetics globally. Type 2 diabetes is really interesting in the context of insulin.

Marc: Most people with insulin resistance are sedentary or overweight—about 80% to 90%. But most people with insulin resistance don't get diabetes. Insulin resistance is the precursor. If you are insulin resistant, your pancreas works really hard to keep up.

Marc: For about 25% to 30% of people worldwide, after decades of this, the pancreas becomes exhausted, and that leads to diabetes. So insulin resistance is a risk factor for diabetes, but it isn't diabetes itself. To answer your question, we rarely measure insulin resistance directly.

Marc: The primary way to measure it would be checking insulin levels, but that can be misleading because if your pancreas is failing, your insulin might not be high. Most physicians don't have an easy way to measure insulin resistance, so it's rarely discussed as a disease state.

Marc: Most metabolic researchers feel that insulin resistance underlies all these other conditions.

Brent: Are hemoglobin A1C or blood glucose measures not diagnostic? Blood glucose is a simple test in a comprehensive metabolic panel that costs very little.

Brent: A level between 100 and 125 mg/dL is considered pre-diabetic, and above 125 mg/dL is diabetic. Blood glucose is a short-term measure. Hemoglobin A1C reflects average blood glucose over several months, making it more accurate.

Brent: A level between 5.7% and 6.4% indicates pre-diabetes, and 6.5% or higher indicates diabetes. Hemoglobin A1C is also easy to get. Are you saying these are not diagnostic? If I have a 7% A1C or a blood glucose of 150 mg/dL, is that not a diagnosis of type 2 diabetes?

Marc: No, I agree that's type 2 diabetes. My point is that type 2 diabetes starts with insulin resistance and then progresses. The concept of pre-diabetes has emerged in the last 30 years. Fifty years ago, patients were classified simply as normal or diabetic, but the spectrum is more complex.

Marc: A fasting glucose under 100 mg/dL is normal, 100 to 125 mg/dL is pre-diabetes, and 126 mg/dL or higher is diabetes. A similar sequence applies to hemoglobin A1C. We can identify pre-diabetes because progression is largely driven by the gradual decline of pancreatic function. Insulin resistance is similar in pre-diabetes as it is in frank diabetes.

Marc: The beta cells become progressively depleted. Neither glucose nor A1C are direct markers of insulin resistance itself; they reflect the interaction between insulin resistance and pancreatic function.

Marc: The beta cell is progressively depleted. None of these are perfect markers of insulin resistance alone.

Brent: Identifying pre-diabetes is helpful because medicine has often been too binary—either a green light or a red light. People assume a green light means no changes are needed, and then react with fear when it turns red.

Brent: Telling people they are on the path to type 2 diabetes helps them course-correct earlier. We should apply that approach to every health measure.

Marc: Absolutely. I ran a diabetes clinic at the county hospital in San Francisco for 25 years and taught residents that we won't solve diabetes until clinics like ours close. Diabetes is manageable before full onset. Once diabetes develops, beta cell function degrades.

Marc: Once beta cells burn out, function isn't easily recovered in modern medicine. Early identification is crucial. For instance, women with gestational diabetes have a high risk of developing type 2 diabetes within five years without weight loss.

Marc: If both your parents have type 2 diabetes, you have up to a 90% chance of developing it if you gain weight and remain sedentary. This is a clear trajectory unless interventions occur.

Brent: Your trajectory leads to diabetes if lifestyle changes aren't made.

Marc: If you intervene, you can change that trajectory, but without changes, diabetes will develop.

Brent: Since blood glucose and A1C aren't ideal direct markers and specific insulin resistance tests aren't routinely ordered, what about a fasting insulin test? Fasting insulin seems to be a popular biomarker right now for assessing metabolic health compared to A1C or blood glucose.

Brent: So taking a test first thing in the morning after fasting might give a better indication of metabolic health than hemoglobin A1C or blood glucose.

Marc: Fasting insulin is a reasonable test, though not routine in standard clinical practice. We lack extensive population datasets for insulin comparable to blood glucose or LDL cholesterol.

Marc: Directly measuring insulin resistance requires dynamic testing, such as infusing glucose to observe cellular uptake. If forced to choose a simple measure, fasting insulin is useful, though less validated clinically.

Brent: Are you referring to an oral glucose tolerance test, similar to what is used during pregnancy, or something else?

Marc: Something else. The oral glucose tolerance test assesses diabetes sensitivity, but doesn't directly measure insulin resistance. There is no routine clinical test for insulin resistance, though my lab has researched options.

Marc: Fasting insulin is currently the closest practical option.

Brent: So while standard tests aren't ideal, fasting insulin is the best available option among the choices, even if imperfect.

Brent: That you don't love.

Marc: They are imperfect, and many doctors may not know how to interpret fasting insulin. Addressing insulin resistance, pre-diabetes, or type 2 diabetes relies on similar lifestyle modifications, such as diet and exercise, alongside medications.

Marc: If forced to choose, measuring fasting insulin is a reasonable option.

Brent: Can we transition to heart health markers? You mentioned triglycerides, LDL (often called bad cholesterol), HDL (good cholesterol), and ApoB. High LDL and high ApoB often suggest similar risk profiles and treatment strategies.

Brent: Since metabolic health and heart health overlap, how do you evaluate lipid markers in relation to insulin resistance?

Marc: Insulin resistance is not only relevant to diabetes; elevated insulin correlates with high blood pressure, elevated LDL, high triglycerides, and fatty liver disease.

Marc: Fatty liver affects roughly 90 million Americans, mostly those with obesity, and can progress to liver failure. Historically called nonalcoholic fatty liver disease, it is now referred to as metabolic dysfunction-associated steatotic liver disease.

Marc: It has become a leading cause of liver failure, whereas viral hepatitis and alcohol used to be the primary causes. Fatty liver disease is a helpful example for understanding insulin resistance.

Marc: In insulin resistance, tissues become resistant to insulin's ability to lower blood glucose, but the liver remains sensitive to insulin's signals to synthesize fat. This selective resistance leads to increased fat production in the liver.

Marc: As insulin increases to manage glucose, the liver synthesizes and stores new fat as triglycerides. Accumulating triglycerides in the liver can cause fatty liver disease or elevate blood triglycerides.

Marc: High blood triglycerides contribute to cardiovascular disease. In insulin resistance, the liver produces more triglycerides and packages them into more ApoB particles. Measuring ApoB helps determine the number of atherogenic particles circulating in the blood.

Marc: Small, dense LDL particles and elevated ApoB levels are characteristic of insulin resistance. The liver stays in a fat-synthesizing state because it remains sensitive to insulin's signals for lipogenesis.

Marc: Fat accumulation in the liver causes fatty liver disease, while fat released into the bloodstream contributes to dyslipidemia, both components of metabolic syndrome. Standard LDL levels are influenced more by genetics and dietary patterns, though still connected.

Marc: Cardiovascular disease correlates strongly with insulin resistance through these mechanisms.

Brent: LDL (low-density lipoprotein) contains a higher proportion of fat relative to protein, whereas HDL (high-density lipoprotein) contains more protein and helps transport cholesterol out of tissues.

Brent: ApoB measures the total number of atherogenic particles. While ApoB provides additional detail, high LDL and high ApoB generally lead to similar clinical decisions.

Marc: There's some nuances. But yeah.

Brent: When insulin resistance is high, the liver produces more fat. Fat can be stored as subcutaneous fat (under the skin) or as visceral fat around internal organs.

Brent: Visceral fat accumulates around internal organs and carries greater health risks. It can be measured using imaging like a DEXA scan. Insulin resistance alters lipid profiles and increases visceral fat accumulation, compounding heart disease risk.

Brent: So insulin resistance and heart disease risk build on one another.

Marc: Body fat distribution is nuanced. Obesity is defined by high total body fat, which correlates with insulin resistance, but fat location matters significantly.

Marc: Lipodystrophy is a genetic condition where individuals lack subcutaneous fat entirely.

Marc: Subcutaneous fat influences body shape and fat distribution. Without subcutaneous storage capacity, fat accumulates in ectopic sites.

Marc: People with lipodystrophy develop severe insulin resistance, high triglycerides, fatty liver, diabetes, and cardiovascular disease. When fat cannot be stored subcutaneously, it deposits in organs like the liver, muscle, and pancreas.

Marc: Ectopic and visceral fat carry much higher metabolic risk than subcutaneous fat under the skin.

Brent: So while obesity is linked to poor health outcomes, subcutaneous fat itself is less harmful than visceral fat.

Brent: Is the metabolic risk in individuals with obesity primarily driven by the accompanying visceral fat rather than subcutaneous fat?

Marc: That's fair. Consider sumo wrestlers as an example.

Marc: Sumo wrestlers can weigh 400 pounds but train rigorously for hours daily. While actively training, their fat is stored primarily subcutaneously rather than viscerally.

Marc: They often display normal insulin levels, high HDL, low LDL, and normal blood pressure. When they retire and stop training while maintaining high caloric intake, they accumulate visceral fat and develop hypertension, cardiovascular disease, and diabetes.

Marc: High subcutaneous fat combined with high physical fitness does not produce the same metabolic dysfunction. However, most individuals with high body fat also carry significant visceral fat and have lower fitness levels.

Brent: For metabolic health, you prioritize fasting insulin, followed by hemoglobin A1C and blood glucose.

Brent: What cardiovascular biomarkers do you find most valuable? Standard lipid panels measure triglycerides, LDL, and HDL, with ApoB as an additional option. Which markers do you prefer for heart health assessment?

Traditional cardiovascular markers are effective. Evaluating LDL, HDL, fasting triglycerides, and blood pressure provides a solid baseline. ApoB adds detail, but isn't strictly necessary for most patients.

Marc: Management of traditional risk factors like cholesterol (via statins, other medications, and diet) and blood pressure has significantly reduced heart attack incidence over recent decades.

Marc: Cardiovascular mortality has shifted more toward conditions like heart failure rather than acute heart attacks. Focusing on standard risk factors—blood pressure, lipids, and diabetes—has proven successful.

Brent: Focusing on blood pressure and LDL through treatments like statins has made a clear impact. Older generations frequently experienced sudden fatal heart attacks, which seem less common today.

Brent: Incidents of sudden cardiac death during everyday activities feel less frequent now due to improved preventive care and intervention.

Brent: Sudden death from heart attacks still occurs, but rates appear lower than in past generations.

Marc: Emergency response, defibrillators, and stenting have improved acute cardiac care. Managing basic risk factors—blood pressure, LDL, HDL, and glucose—remains the most effective starting point for most people.

Marc: Monitoring blood pressure, lipids, HDL, and diabetes risk covers the essential risk factors.

Brent: Have you researched measures of how efficiently the body clears LDL particles? While harder to measure than static LDL or HDL levels, particle clearance rate might provide additional risk insight.

Brent: Is particle clearance testing a metric that might become useful in future clinical practice?

Marc: We studied reverse cholesterol transport, the process where HDL removes cholesterol from arteries and returns it to the liver for excretion.

Marc: Measuring cholesterol flux is technically complex and not feasible for standard care. Effective drugs to raise HDL directly do not currently exist, so flux testing remains primarily a research tool.

Marc: Selective insulin resistance is an important concept: different metabolic pathways in the body don't become resistant equally. This is particularly relevant in fatty liver disease.

Marc: I view insulin resistance not as a disease, but as an evolutionary program responding to chronic overfeeding and physical inactivity. The body signals that it has sufficient energy, limiting further uptake of glucose and fat.

Marc: Treating insulin resistance without weight loss is difficult because it is a physiological response to excess caloric intake relative to expenditure in modern environments.

Brent: It's an adaptive biological response to surplus energy. Modern conveniences allow us to obtain food, climate control, and transport without significant physical exertion.

Brent: Our biology evolved to handle scarcity rather than continuous caloric surplus, leading to widespread insulin resistance in modern settings.

Brent: So insulin resistance develops as a secondary consequence of that environmental mismatch.

Marc: Human physiology has strong evolutionary protections against starvation, preserving critical muscle mass during food deficits, but lacks robust mechanisms to handle continuous surpluses.

Marc: Insulin resistance behaves like a biological program. Short-term overfeeding for five days induces measurable insulin resistance. Liver glycogen stores saturate, causing continuous glucose release into the blood despite elevated insulin.

Marc: As adipose tissue fills with triglycerides, fat breakdown increases to release excess stored lipids. The body actively tries to shed excess energy stores.

Marc: Short-term caloric restriction demonstrates this rapidly. In studies of individuals with type 2 diabetes, five days of severe caloric restriction significantly reduced hepatic glucose production, fasting blood sugar, and insulin levels.

Marc: Recent energy intake directly affects insulin sensitivity. Brief dietary interventions improve acute metabolic markers, but long-term maintenance remains the main challenge.

Marc: A short period of strict dietary restriction noticeably improves insulin markers, but sustaining those habits long term is difficult.

Brent: What is your perspective on fasting? Views on fasting have varied, with interest shifting over time. Is fasting useful for treating insulin resistance, or are its benefits overstated?

Brent: Is fasting something everyone should practice, or is its value specific to certain conditions?

Marc: Human physiology responds effectively to fasting through broad hormonal and metabolic shifts, though evidence that it extends human lifespan remains inconclusive.

Brent: How do you define a fast? Is it 8 hours, 12 hours, or longer?

Marc: A fast means consuming no calories or protein for a designated period, whether several hours or multiple days.

Brent: Is there a minimum duration, such as 8 hours?

Marc: An 8 to 10 hour overnight period yields a standard fasting glucose reading. When discussing therapeutic fasting, periods are much longer. Much of the longevity data comes from rodent models.

Marc: A 24-hour fast in a rodent represents metabolic shifts similar to a multi-week fast in humans. Prolonged fasting in humans reduces metabolic rate, shifts brain fuel to ketones, exhausts glycogen, and lowers insulin and glucose, but also leads to lean tissue loss.

Marc: Because multi-week fasts aren't practical, researchers have studied intermittent fasting strategies to evaluate if periodic calorie restriction safely triggers similar metabolic adaptations.

Marc: Continuous severe hunger isn't sustainable for most people. Intermittent fasting explores whether alternating normal eating with low-calorie days activates beneficial fasting pathways.

Marc: In rodents, a 30% continuous caloric reduction extends lifespan by up to 50%. However, translating rodent fasting protocols directly to humans requires cautious interpretation given metabolic rate differences.

Marc: Multi-day or alternate-week fasts are difficult for most people to maintain long term.

Brent: How tolerable is extended fasting? How would someone feel during a six-day fast?

Marc: Some experience mental clarity once ketosis establishes, but fatigue, reduced concentration, sleep disruption, and decreased physical energy are common during prolonged fasts.

Marc: During severe involuntary starvation, the body conserves energy by suppressing physical activity and reducing cognitive expenditure.

Brent: Can a healthy person fast for seven days without long-term harm, provided they can tolerate the discomfort?

Marc: Protein loss is highest in the first few days of a fast. Once ketosis develops around day three, the brain utilizes ketone bodies for fuel, decreasing protein breakdown and slowing lean mass loss.

Marc: Healthy individuals recover lost muscle mass upon refeeding, though extended fasting remains physically challenging.

Marc: Alternate-day fasting protocols are more manageable for many people than continuous multi-day fasts.

Brent: Alternate-day fasting involves eating normally one day and fasting for the next 24 hours in a repeating cycle.

Marc: Alternate-day fasting usually leads to weight loss because consuming double calories on non-fasting days is difficult. Some modified fasts permit around 20% of typical caloric intake on fasting days to improve adherence.

Marc: Continuous 30% caloric restriction feels unappealing to many, whereas alternating eating and fasting days feels more manageable for some people.

Marc: While alternate-day fasting shows potential, robust long-term human trial data on longevity outcomes remains limited. Caloric restriction studies in rodents clearly demonstrate substantial lifespan extension under controlled laboratory conditions.

Marc: The ability of simple caloric reduction to significantly extend rodent lifespan is a remarkable biological observation.

Brent: In laboratory settings, caloric intake is fully controlled. For humans, maintaining dietary restriction requires ongoing willpower amid abundant food options.

Brent: Adhering to alternate-day fasting is challenging when surrounded by food choices.

Marc: Adherence involves physiological drives alongside willpower. Intermittent fasting may not serve as a universal public health solution, but understanding its underlying protective pathways could help identify targets to promote healthy aging.

Brent: If intermittent fasting were widely adopted, do you think average human lifespan would increase significantly?

Marc: Intermittent fasting alone may not dramatically extend maximum human lifespan.

Brent: What is your best estimate of its potential impact?

Marc: Physical fitness exerts a clearer protective effect on healthy aging than caloric restriction alone. Individuals with higher body weight who maintain good cardiorespiratory fitness have lower risks of cardiovascular disease, diabetes, and fatty liver than sedentary individuals with lower body weight.

Marc: Observational studies tracking individuals over time demonstrate that physical fitness mitigates many metabolic risks associated with higher body fat.

Marc: Cardiorespiratory fitness provides substantial health protection. High-level athletes with higher body mass demonstrate that cardiorespiratory fitness preserves metabolic health.

Marc: Active sumo wrestlers and athletic swimmers with higher body fat illustrate that high physical activity supports favorable metabolic markers.

Marc: Prioritizing cardiorespiratory fitness offers broader health benefits than focusing solely on reducing body fat.

Brent: Does fat distribution contribute to sex differences in survival during severe hardship? Historically, women have demonstrated higher survival rates than men in extreme famine conditions, such as the Donner Party incident.

Brent: Women generally have higher average body fat percentages and longer life expectancies than men. Is that advantage related to fat distribution and energy mobilization during stress?

Brent: Women tend to outlive men overall.

Marc: Women mobilize stored body fat more effectively during starvation compared to men.

Brent: Meaning women can endure starvation conditions longer than men?

Marc: Yes, women generally endure severe caloric restriction somewhat longer than men.

Brent: Historical events show higher survival rates for women during famine.

Marc: The general life expectancy advantage in women—roughly four additional years on average—is largely driven by cardiovascular protection linked to estrogen, which supports favorable lipid profiles compared to testosterone.

Marc: Post-menopausal women lose some of that cardiovascular protection as estrogen levels decline, indicating that hormonal factors account for much of the sex difference in cardiovascular longevity.

Brent: What is the relationship between insulin resistance and sarcopenia—the age-related decline in muscle mass and strength?

Brent: Maintaining muscle mass is vital as we age to prevent falls and mobility loss. How do sarcopenia and insulin resistance interact?

Marc: Sarcopenia refers to the loss of skeletal muscle mass and function with aging. Muscle loss increases weakness, fall risk, and mobility disability, reducing independence.

Marc: Muscle mass is essential for insulin sensitivity and functional capacity in older adults. Currently, few pharmacological options effectively restore muscle mass in older populations.

Marc: My colleague Bill Evans and I developed a diagnostic method to quantify total muscle mass. Tracking body composition and muscle mass provides valuable health insight.

Marc: Gait speed correlates strongly with functional longevity and overall mortality risk in older adults, serving as a meaningful indicator of physical health.

Marc: Muscle mass influences healthspan and metabolic function. Insulin resistance reduces the anabolic stimulation needed to build and maintain muscle tissue, contributing to weakness.

Targeting muscle insulin action is a key area for future research.

Brent: So if two individuals follow identical resistance training programs, the person with higher insulin resistance will likely gain muscle at a slower rate.

Marc: That alignment is biologically expected. However, regular resistance training improves insulin sensitivity directly, making isolated comparisons complex.

Marc: Insulin resistance, particularly in older adults with diabetes, accelerates muscle loss and weakness, contributing to frailty and fracture risks.

Marc: Accelerated muscle loss significantly worsens clinical outcomes.

Brent: What is your perspective on GLP-1 receptor agonists? While effective for treating obesity, what is their role in preventive health or low-dose applications for non-obese individuals seeking general metabolic optimization?

Brent: How do you view GLP-1 medications for general longevity and preventive health outside of primary obesity treatment?

Marc: Robust trial data for GLP-1 use in non-obese populations for longevity is currently lacking. GLP-1 receptor agonists represent a major therapeutic advance for obesity management and metabolic disease, but they exert wide-ranging systemic effects.

Marc: GLP-1 therapies dampen reward signaling, which reduces appetite and addictive behaviors (like smoking or alcohol intake), but may also reduce enjoyment from everyday activities. Long-term adherence remains a question, as many patients discontinue use within a year.

Marc: Discontinuation may stem from side effects, medication costs, or reduced food enjoyment. Weight is typically regained after stopping treatment. Microdosing strategies lack formal study data.

Marc: GLP-1 agonists are effective tools for weight loss and appetite suppression, though reducing appetite inherently alters the pleasure associated with eating.

Brent: Because GLP-1 agonists act on central reward pathways, they might diminish enjoyment in other areas of life alongside appetite suppression.

Marc: Dampening central reward pathways represents a significant neurochemical change. An ideal treatment might increase metabolic rate directly, but suppressing appetite via GLP-1 agonists is currently our most effective option.

Marc: Reducing body weight improves insulin sensitivity. However, whether GLP-1 therapies independently extend human lifespan outside of weight reduction remains unstudied.

Marc: GLP-1 medications help sustain appetite suppression continuously during active treatment, unlike conventional restrictive diets where hunger eventually undermines adherence.

Brent: GLP-1 agonists modulate hormonal appetite drives directly, reducing the reliance on conscious willpower to resist excess food intake.

Marc: They reduce appetite directly, lowering interest in food and caloric consumption.

Brent: GLP-1 agonists achieve appetite suppression with a cleaner safety profile compared to older appetite suppressants like amphetamines.

Marc: Amphetamines carry high addiction potential, cardiovascular risks, and behavioral side effects. GLP-1 therapies provide a safer mechanism for appetite suppression.

Marc: GLP-1 is an intestinal peptide released after meals to promote satiety and stimulate insulin secretion. Utilizing an endogenous hormonal pathway makes GLP-1 agonists a well-targeted intervention.

Marc: At pharmacological doses, GLP-1 agonists sustain high satiety signals continuously.

Brent: Dr. Hellerstein, looking ahead 50 years, what research topic or scientific question would you be most curious to look up?

Brent: If you had access to all scientific discoveries over the next half-century, which field or discovery would interest you most?

Marc: Identifying a pathway that stimulates intrinsic motivation for physical activity—similar to natural drives for food or rewarding behavior—would be transformative. Activating hypothalamic exercise drive would offer significant health benefits globally.

Brent: Thank you, Dr. Hellerstein, for your contributions to metabolic research, teaching, and for sharing your time with us today.

Marc: Thanks, Brent. I appreciate it.

Brent: The Life Lab by Death Clock is recorded in Boulder, Colorado, and San Francisco, California. Produced by Patrick Godinho, with music by Patrick Lee, and hosted by Brent Franson, founder and CEO of Death Clock.